Romiplostim (Nplate) — Coverage Criteria for ITP and HSARS
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization, and site-of-care requirements for romiplostim (Nplate) subcutaneous injection for treatment of immune thrombocytopenia (ITP) and Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS) for Blue Cross NC members.
Reformatted chronic ITP criteria to allow either platelet count ≤ 30 x 10^9/L or platelet count < 50 x 10^9/L with symptomatic bleeding/increased bleeding risk and adjusted trial/failure requirements; added specialist prescriber and prohibition on combination use with other thrombopoietin receptor agonists; extended ITP initial approval to 90 days.
Added HCPCS code J2802 to dosing reference table and adjusted maximum units according to coding unit definition.
Added and clarified Site of Care medical necessity criteria including bypass conditions for inpatient/outpatient hospital administration.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.